<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02429570</url>
  </required_header>
  <id_info>
    <org_study_id>15-068</org_study_id>
    <nct_id>NCT02429570</nct_id>
  </id_info>
  <brief_title>Meclofenamate in Subjects With Recurrent or Progressive Brain Metastasis From Solid Tumor Primary</brief_title>
  <official_title>Pilot Study of Meclofenamate in Subjects With Recurrent or Progressive Brain Metastasis From Solid Tumor Primary</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Memorial Sloan Kettering Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Memorial Sloan Kettering Cancer Center</source>
  <brief_summary>
    <textblock>
      Cancer that has spread to the brain, or brain metastasis, is difficult to treat.&#xD;
      Meclofenamate is a drug which has been shown to reduce brain metastasis growth in the&#xD;
      laboratory. This medicine has been used in the past to treat pain. But, in this study, it&#xD;
      will be used to prevent new brain metastasis. This is the first time that meclofenamate will&#xD;
      be used in patients with brain metastasis.&#xD;
&#xD;
      This is a pilot study which means that the purpose of this study is to determine if a larger&#xD;
      clinical trial of meclofenamate is possible in patients with brain metastasis. This study&#xD;
      also aims to find out what effects, good and/or bad meclofenamate has on the patient and the&#xD;
      cancer that has spread to the brain. The investigators also want to learn more about&#xD;
      potential effects that this drug may have in the digestive system.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">April 22, 2015</start_date>
  <completion_date type="Anticipated">April 2022</completion_date>
  <primary_completion_date type="Anticipated">April 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Feasible (if at least 50% of patients enrolled are evaluable in brain by MRI at the 2-month timepoint)</measure>
    <time_frame>2 month</time_frame>
    <description>The trial will be deemed &quot;feasible&quot; if at least 50% of patients enrolled are evaluable in brain by MRI at the 2-month timepoint.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>1 year</time_frame>
    <description>Adverse events (from all categories) will be collected, graded according to version 4.0 of the NCI Common Terminology Criteria for Adverse Events.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>1 year</time_frame>
    <description>progression-free survival is defined as time from start of treatment to progressive disease by MRI</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Recurrent Brain Metastases</condition>
  <condition>Progressive Brain Metastases</condition>
  <arm_group>
    <arm_group_label>Meclofenamate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All enrolled patients will receive the study drug, meclofenamate at 100 mg PO BID.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Meclofenamate</intervention_name>
    <arm_group_label>Meclofenamate</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 18-80&#xD;
&#xD;
          -  KPS ≥ 60&#xD;
&#xD;
          -  At least one recurrent or progressive brain metastasis (es) from any solid primary&#xD;
             tumor that is visible on MRI as assessed by the patient's treating physician.&#xD;
&#xD;
          -  Recurrence may occur after any treatment: recurrence after whole-brain radiation,&#xD;
             stereotactic radiosurgery, surgical resection, systemic chemotherapy are all&#xD;
             acceptable.&#xD;
&#xD;
          -  There is no limit on the number of brain metastases.&#xD;
&#xD;
          -  Surgical resection or SRS to other recurrent lesions in the same patient are&#xD;
             acceptable, provided one recurrent lesion remains untreated.&#xD;
&#xD;
          -  Systemic disease must be well-controlled or NED in the opinion of the patient's&#xD;
             primary oncologist.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Inability to get brain MRI +/- contrast&#xD;
&#xD;
          -  Progressive systemic disease&#xD;
&#xD;
          -  Known leptomeningeal metastases&#xD;
&#xD;
          -  Primary Brain tumor&#xD;
&#xD;
          -  Active Intracranial Hemorrhage&#xD;
&#xD;
          -  Surgery less than two weeks before enrollment&#xD;
&#xD;
          -  GI hemorrhage (active or in recent 6 months)&#xD;
&#xD;
          -  Concurrent anti-platelet therapy&#xD;
&#xD;
          -  Concurrent anti-coagulation therapy&#xD;
&#xD;
          -  Active bleeding diathesis&#xD;
&#xD;
          -  Platelet count ≤ 70,000/mm3&#xD;
&#xD;
          -  International normalized ratio (INR) &gt; 1.6 and a Partial Thromboplastin Time (PTT) &gt;&#xD;
             40 seconds&#xD;
&#xD;
          -  Serum Creatinine &gt;2 mg/dL OR CrCL &lt;30ml/min&#xD;
&#xD;
          -  AST or ALT &gt; 200 U/L&#xD;
&#xD;
          -  Hemoglobin &lt;8 g/dL&#xD;
&#xD;
          -  Allergy to meclofenamate or other NSAID&#xD;
&#xD;
          -  Inability to tolerate PO dosing&#xD;
&#xD;
          -  Steroid dose increased in the most recent two weeks.&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Cardiac Arrhythmia requiring medical management and/or pacemaker.&#xD;
&#xD;
          -  Known congestive heart failure requiring medical management&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Adrienne Boire, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Memorial Sloan Kettering Cance Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Baptist Health South Florida</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memoral Sloan Kettering Cancer Center</name>
      <address>
        <city>Basking Ridge</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Monmouth</name>
      <address>
        <city>Middletown</city>
        <state>New Jersey</state>
        <zip>07748</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center at Commack</name>
      <address>
        <city>Commack</city>
        <state>New York</state>
        <zip>11725</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Westchester</name>
      <address>
        <city>Harrison</city>
        <state>New York</state>
        <zip>10604</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lehigh Valley Health Network</name>
      <address>
        <city>Allentown</city>
        <state>Pennsylvania</state>
        <zip>18103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mskcc.org/</url>
    <description>Memorial Sloan Kettering Cancer Center</description>
  </link>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>April 22, 2015</study_first_submitted>
  <study_first_submitted_qc>April 28, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 29, 2015</study_first_posted>
  <last_update_submitted>May 4, 2021</last_update_submitted>
  <last_update_submitted_qc>May 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>meclofenamate</keyword>
  <keyword>15-068</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Neoplasms, Second Primary</mesh_term>
    <mesh_term>Brain Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Meclofenamic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

